Answers are grounded in this paper and cite their sources.
Acute kidney injury (AKI) is a life-threatening organ dysfunction associated with poor clinical prognosis. The incidence of AKI in intensive care unit (ICU) patients can reach up to 50%. Cardiac surgery-associated AKI (CSA-AKI) increases in-hospital mortality by 3 to 8 times in patients undergoing cardiac surgery, while its early recognition and diagnosis remain challenging in clinical practice. Annexin-A1 (ANX-A1), also known as lipocortin I, can alleviate inflammatory response in ischemia-reperfusion injury related to myocardial infarction and stroke; however, its role as a potential biomarker for CSA-AKI has not been reported. Therefore, this study aimed to explore the predictive value of ANX-A1 for CSA-AKI. We conducted a single-center prospective cohort study, enrolling 160 adult patients who underwent on-pump cardiac surgery and were transferred to the ICU postoperatively. Patients aged < 18 years, pregnant patients, those who did not provide informed consent, and those with pre-existing chronic kidney disease or preoperative renal replacement therapy (RRT) were excluded. Perioperative clinical data were prospectively collected. CSA-AKI was diagnosed according to the 2012 Kidney Disease Improving Global Outcomes (KDIGO) AKI guidelines. Restricted cubic splines (RCS) were used to characterize the association between ANX-A1 levels and CSA-AKI risk. Logistic regression models were constructed to identify independent factors associated with CSA-AKI; receiver operating characteristic (ROC) curves with area under the curve (AUC) were used to evaluate the predictive value of ANX-A1 for CSA-AKI; Kaplan-Meier curves with log-rank test were used to compare the cumulative risk of CSA-AKI between groups stratified by the optimal ANX-A1 cut-off value. Among the 160 enrolled patients undergoing on-pump cardiac surgery, 63 (39.38%) developed CSA-AKI. Postoperative ANX-A1 level < 6.189 ng/mL was associated with a significantly higher risk of CSA-AKI (log-rank p < 0.001); ANX-A1 was an independent protective factor for CSA-AKI (adjusted odds ratio [OR] = 0.83, 95% confidence interval [CI]: 0.70–0.98, P = 0.033). The AUC of ANX-A1 for predicting CSA-AKI was 0.629 (95%CI: 0.539–0.713, P = 0.006), and the combination of ANX-A1 with gender, EuroSCORE, and aortic cross-clamp time increased the AUC to 0.817 (95%CI: 0.750–0.879, P < 0.001). Lower postoperative ANX-A1 levels were also associated with longer AKI duration, higher requirement for RRT, longer ICU stay, and longer postoperative hospital stay. Postoperative serum ANX-A1 level is independently associated with the incidence of CSA-AKI in adult patients undergoing cardiac surgery, and has moderate early predictive value for CSA-AKI. The combination of ANX-A1 with conventional clinical indicators can further improve the predictive efficacy for CSA-AKI. ANX-A1 may help identify high-risk patients of CSA-AKI in the early stage, while its clinical transformation value needs to be further verified by multi-center and large-sample prospective studies.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: